CN BIO INNOVATIONS LIMITED
Get an alert when CN BIO INNOVATIONS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-03-12 (in 10mo)
Last made up 2026-02-26
Watchouts
None on the register
Cash
£10M
+1,430.9% highest in 4 filed years
Net assets
£13M
+290.6% highest in 4 filed years
Employees
49
+14% highest in 4 filed years
Profit before tax
-£6M
-13.1% lowest in 4 filed years
Net assets
4-year trend · vs Technology median
Accounts
4-year trend · latest reflected 2024-12-31
| Metric | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Turnover | £1,672,453 | £2,131,336 | £3,425,098 | £3,467,383 | |
| Operating profit | -£3,008,021 | -£3,931,799 | -£5,094,969 | -£6,142,752 | |
| Profit before tax | -£3,013,297 | -£4,120,789 | -£5,521,172 | -£6,242,817 | |
| Net profit | -£3,013,297 | -£4,120,789 | -£5,521,172 | -£6,332,622 | |
| Cash | £248,672 | £3,399,215 | £650,669 | £9,961,406 | |
| Total assets less current liabilities | £2,020,404 | £5,902,343 | -£6,555,144 | £12,578,692 | |
| Net assets | £932,004 | -£1,493,950 | -£6,584,498 | £12,552,925 | |
| Equity | £932,004 | -£1,493,950 | -£6,584,498 | £12,552,925 | |
| Average employees | 36 | 45 | 43 | 49 | |
| Wages | — | — | £3,047,161 | £3,273,289 | |
| Directors' remuneration | — | — | £190,806 | £220,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+1.2%
£3,425,098 £3,467,383
highest in 4 filed years
-
Cash
+1,430.9%
£650,669 £9,961,406
highest in 4 filed years
-
Net assets
+290.6%
-£6,584,498 £12,552,925
highest in 4 filed years
-
Employees
+14%
43 49
highest in 4 filed years
-
Operating profit
-20.6%
-£5,094,969 -£6,142,752
lowest in 4 filed years
-
Profit before tax
-13.1%
-£5,521,172 -£6,242,817
lowest in 4 filed years
-
Wages
+7.4%
£3,047,161 £3,273,289
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Operating margin | -179.9% | -184.5% | -148.8% | -177.2% | |
| Net margin | -180.2% | -193.3% | -161.2% | -182.6% | |
| Return on capital employed | -148.9% | -66.6% | 77.7% | -48.8% | |
| Current ratio | — | — | 0.29x | 10.16x | |
| Interest cover | -499.75x | -20.80x | -10.75x | -17.84x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- CN BIO INNOVATIONS LIMITED 2014-01-23 → present
- ZYOXEL LIMITED 2008-10-16 → 2014-01-23
- M&R 1070 LIMITED 2008-02-28 → 2008-10-16
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the current business plan, the Company's cash and cash equivalents will be sufficient for the business until the first quarter of 2027, without the need for the implementation of any mitigating cost saving measures. To continue with the current business plan after this date, the Company expects additional funding is required.”
Group structure
- CN BIO INNOVATIONS LIMITED · parent
- 28 North Discovery Limited 100%
Significant events
- “The Company has continued to successfully raise further equity funding with additional external capital investment of £12.2M in June 2024 and £4.3M in July 2024.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BROOKS, Paul Robert, Dr | Director | 2023-01-01 | Dec 1968 | British |
| CHONG, Hok Hei Charles, Mr. | Director | 2011-08-31 | Dec 1958 | British |
| CHOW, Ka Lok Kevin, Dr | Director | 2025-03-31 | Jan 1978 | Hong Konger |
| COLEMAN, Maureen Sheila Helen | Director | 2010-04-27 | Apr 1953 | British |
| SCALES, Michael David Courtney | Director | 2018-12-20 | Jan 1952 | British |
| TONG, Fung Cheuk, Dr | Director | 2023-01-01 | May 1959 | Hong Konger |
| TSE, Andy Po Shing | Director | 2009-07-10 | Jul 1966 | Chinese |
| YIN, Wang | Director | 2024-06-25 | May 1986 | Chinese |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LIM, Zickie | Secretary | 2008-02-28 | 2008-11-17 |
| M&R SECRETARIAL SERVICES LIMITED | Corporate Secretary | 2008-11-17 | 2015-03-26 |
| BRINDLE, Stephen | Director | 2010-07-02 | 2016-03-29 |
| CUI, Zhanfeng, Professor | Director | 2008-11-17 | 2015-01-21 |
| D'ABBADIE, Marc Francois | Director | 2009-07-10 | 2009-09-18 |
| HART, Timothy David, Dr | Director | 2008-11-17 | 2012-10-18 |
| HUGHES, David James, Dr | Director | 2015-07-27 | 2022-11-16 |
| PICKTHORN, Tom | Director | 2008-02-28 | 2008-11-17 |
| SCEATS, Emma Louise, Dr | Director | 2014-06-30 | 2018-07-18 |
| SU, Yuexing | Director | 2024-06-04 | 2025-03-31 |
| XIONG, Anqi | Director | 2019-09-25 | 2024-06-25 |
| YIP, Kwok Keong | Director | 2009-07-10 | 2011-08-31 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 143 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-24 | CH01 | officers | Change person director company with change date | |
| 2025-11-24 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-11-20 | CH01 | officers | Change person director company with change date | |
| 2025-08-19 | AA | accounts | Accounts with accounts type full | |
| 2025-04-02 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-02 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-05 | AA | accounts | Accounts with accounts type full | |
| 2024-11-15 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-08-29 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2024-08-09 | SH01 | capital | Capital allotment shares | |
| 2024-07-13 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2024-07-05 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 11
- Capital events
- 3
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.